Jammu And Kashmir Headlines

Alzheimer’s disease Pipeline Drugs Analysis Report, (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Alzheimer’s disease Pipeline Drugs Analysis Report, (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 03
19:30 2023
Alzheimer’s disease Pipeline Drugs Analysis Report, (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Alzheimer’s disease Pipeline
As per DelveInsight’s assessment, globally, Alzheimer’s disease pipeline constitutes 150+ key companies continuously working towards developing 160+ Alzheimer’s disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

(Las Vegas, Nevada, United States) “Alzheimer’s disease Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer’s disease Market.

The Alzheimer’s disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Click here to know more about the Alzheimer’s’ disease drugs in different phases of development @ Alzheimer’s disease pipeline analysis

 

Some of the key takeaways from the Alzheimer’s disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Alzheimer’s disease treatment therapies with a considerable amount of success over the years. 
  • Alzheimer’s disease companies working in the treatment market are Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others, are developing therapies for the Alzheimer’s disease treatment 
  • Emerging Alzheimer’s disease therapies such as – ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others are expected to have a significant impact on the Alzheimer’s disease market in the coming years.   
  • In February 2023, Lantheus Holdings, Inc. announced it had acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease.Under the terms of the agreement, Lantheus will pay an upfront payment and potential additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales.
  • In January 2023, Prothena Corporation plc announced positive topline Phase I single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. The results of the study found all three dose level cohorts of PRX005 to be generally safe and well tolerated, meeting the Phase 1 SAD study primary objective. None of the treatment emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters. PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints.

 

Alzheimer’s disease Overview

Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease — those with the late-onset type symptoms first appear in their mid-60s. Early-onset Alzheimer’s occurs between a person’s 30s and mid-60s and is very rare. Alzheimer’s disease is the most common cause of dementia among older adults. Memory problems are typically one of the first signs of Alzheimer’s, though initial symptoms may vary from person to person. A decline in other aspects of thinking, such as finding the right words, vision/spatial issues, and impaired reasoning or judgment, may also signal the very early stages of Alzheimer’s disease. 

 

Get a Free Sample PDF Report to know more about Alzheimer’s disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight

 

Emerging Alzheimer’s disease Drugs Under Different Phases of Clinical Development Include:

  • Donanemab: Eli Lilly and Company
  • Ibuprofen/sodium cromoglicate: AZTherapies
  • Simufilam: Cassava Sciences
  • Masitinib: AB Science
  • Pegipanermin: INmune Bio
  • IBC-Ab002: Immunobrain Checkpoint 

 

Route of Administration

Alzheimer’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Alzheimer’s disease Pipeline Therapeutics Assessment

  • Alzheimer’s disease Assessment by Product Type
  • Alzheimer’s disease By Stage and Product Type
  • Alzheimer’s disease Assessment by Route of Administration
  • Alzheimer’s disease By Stage and Route of Administration
  • Alzheimer’s disease Assessment by Molecule Type
  • Alzheimer’s disease by Stage and Molecule Type

 

DelveInsight’s Alzheimer’s disease Report covers around 160+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Alzheimer’s disease product details are provided in the report. Download the Alzheimer’s disease pipeline report to learn more about the emerging Alzheimer’s disease therapies – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight

 

Alzheimer’s disease Pipeline Analysis:

The Alzheimer’s disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer’s disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s disease Treatment.
  • Alzheimer’s disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Alzheimer’s disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer’s disease market.

 

Download Sample PDF Report to know more about Alzheimer’s disease drugs and therapies – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight

 

Scope of Alzheimer’s disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Alzheimer’s disease Companies: Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others.
  • Key Alzheimer’s disease Therapies: ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others
  • Alzheimer’s disease Therapeutic Assessment: Alzheimer’s disease current marketed and Alzheimer’s disease emerging therapies
  • Alzheimer’s disease Market Dynamics: Alzheimer’s disease market drivers and Alzheimer’s disease market barriers 

 

Request for Sample PDF Report for Alzheimer’s disease Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight

 

Table of Contents

1

Alzheimer’s disease Report Introduction

2

Alzheimer’s disease Executive Summary

3

Alzheimer’s disease Overview

4

Alzheimer’s disease- Analytical Perspective In-depth Commercial Assessment

5

Alzheimer’s disease Pipeline Therapeutics

6

Alzheimer’s disease Late Stage Products (Phase II/III)

7

Alzheimer’s disease Mid Stage Products (Phase II)

8

Alzheimer’s disease Early Stage Products (Phase I)

9

Alzheimer’s disease Preclinical Stage Products

10

Alzheimer’s disease Therapeutics Assessment

11

Alzheimer’s disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Alzheimer’s disease Key Companies

14

Alzheimer’s disease Key Products

15

Alzheimer’s disease Unmet Needs

16 

Alzheimer’s disease Market Drivers and Barriers

17

Alzheimer’s disease Future Perspectives and Conclusion

18

Alzheimer’s disease Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting